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Abstract: Vitamin D deficiency is highly prevalent amongst pregnant women and is linked to a range
of adverse complications, including gestational diabetes. However, there is no consensus among
researchers regarding the impact of vitamin D supplementation in alleviating adverse effects in
gestational diabetes. The objective of this systematic review and meta-analysis was to determine
whether supplementation of vitamin D given to women with gestational diabetes can promote
glycaemic control. EMBASE and PubMed were searched up to November, 2018. The selection criteria
included randomised controlled trials of the effect of vitamin D supplementation (1000–4762 IU/day)
on pregnant women with gestational diabetes mellitus. Study data and outcome measures (fasting
blood glucose, glycated haemoglobin and serum insulin) were extracted from included studies.
Random-effects models were used for meta-analyses. Heterogeneity tests, and analysis of the risk
of bias were conducted. Most of the studies were graded as having either low risk or moderate
risk of bias although two studies had a high risk of bias in the areas of blinding of participants
and personnel, and incomplete outcome data. On the other hand, the heterogeneity statistic (I2)
ranged from 0–41% in the studies included. Five randomised controlled trials were selected for this
review and meta-analysis (involving a total of 173 participants supplemented with vitamin D and
153 participants as control drawn from the studies). Vitamin D supplementation was associated with
a decrease in fasting blood glucose by a mean of 0.46 mmol/L (−0.68, −0.25) (p < 0.001), glycated
haemoglobin by a mean of 0.37% (−0.65, −0.08) (p < 0.01) and serum insulin concentration by mean
of 4.10 µIU/mL (−5.50, −2.71) (p < 0.001) compared to controls. This review shows evidence that
vitamin D supplementation has the potential to promote glycaemic control in women with Gestational
Diabetes Mellitus (GDM). However, due to the limited number of studies in the meta-analysis, the
conclusion should be interpreted with caution. Further studies are needed to fully understand the
exact mechanism by which vitamin D influences glucose metabolism.
Keywords: Gestational Diabetes Mellitus; Vitamin D supplementation; meta-analysis; pregnancy; insulin
1. Introduction
Gestational Diabetes Mellitus (GDM) results from beta cell dysfunction and/or insulin resistance
which leads to hyperglycaemia and is unique to pregnancy [1–3]. Globally, it affects an estimated 1 in
7 live births [4]. Individuals with GDM are also at risk of developing type 2 diabetes in future and
their offspring are at risk of developing childhood obesity and type 2 diabetes later in life [5,6]. A large
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proportion of cases are seen in low and middle-income countries, where access to maternity care is
sparse, exasperating the issue further [4]. Diabetes Mellitus (DM) which antedates pregnancy is not
classified as GDM. Instead, these women are diagnosed as having DM and pregnancy [3]. The World
Health Organisation (WHO) has recently developed guidelines [5] creating a clear distinction that
hyperglycaemia first recognised during pregnancy should be classified either as DM in pregnancy
or GDM. There is evidence from a systematic review of cohort studies that hyperglycaemia detected
during pregnancy is a risk factor for adverse pregnancy outcomes, including macrosomia of new-born
and pre-eclampsia [5].
While well-established risk factors for GDM include high maternal age, maternal overweight or
obesity, family history of type 2 diabetes, evidence linking GDM to vitamin D deficiency is growing
although it remains inconsistent [6]. Vitamin D deficiency in pregnancy may result in the last trimester
of pregnancy due to rapid foetal development, including bone mineralization and calcification [7].
In addition, low exposure to ultraviolet B sunlight, inadequate dietary intake, dark skin colour, veils
and obesity, which may result from decreased bioavailability due to increased deposition in fat cells
may predispose pregnant women to low vitamin D status [8]. Vitamin D deficiency is common in
pregnancy and prevalence varies from 1–90% globally, and with the highest deficiencies seen in the
Middle East [7,9,10].
The role of vitamin D in GDM is particularly important as there is emerging evidence that
suggests that supplementation of vitamin D can improve insulin sensitivity and glucose intolerance
and might control metabolic changes, including hyperglycaemia in pregnancy [9]. According to
De-Regil et al. [11], vitamin D helps in maintaining glucose homeostasis by binding and activating
vitamin D receptors in the pancreatic beta cells and regulating insulin production in relation to the
level of blood glucose. In addition, vitamin D indirectly affects glucose metabolism through its effect
on calcium homeostasis [11].
Vitamin D is also known as calciferol which has 2 forms, vitamin D2 (ergocalciferol) and vitamin
D3 (cholecalciferol) [9]. Both ergocalciferol and cholecalciferol are pro-hormones which are hydrolysed
first to 25-hydroxyvitamin D in the liver which is the main circulating metabolite [12] and then
hydrolysed to calcitriol (1, 25-dihydroxyvitamin D-1,25(OH)2D) in the kidney [9]. There is evidence
that the concentration of the active form, 1,25(OH)2D, increases by 100% or more, during pregnancy
and this has been partly attributed to an estrogen-dependent increase in vitamin D binding globulin,
essential for immune function, thus suggesting extra-skeletal effects of vitamin D [8].
Deficiency of vitamin D is highly prevalent among pregnant women and it has been linked to a range
of adverse complications, including GDM [7]. However, despite several studies, there appears to be no
consensus among researchers with respect to the role of vitamin D supplementation in terms of need, safety
and effectiveness in GDM [13]. In particular, previous systematic reviews and meta-analyses of vitamin
D supplementation and gestational diabetes were based on either observational, cohort, or case-control
studies and not specifically Randomised Controlled Trials (RCTs) [6,8,14–16], or focused on economic
implications [17], involved women without gestations diabetes [11,18], were limited in scope [19–21],
included co-supplementation or had conflicting results and conclusions [22,23]. For example, the
Roth et al. [23] review included trials of prenatal vitamin D supplementation given alone or in combination
with a co-intervention, while the Akbari et al. [22] review involved studies on post-partum (after delivery)
women and co-supplementation with calcium. Agarwal et al. [19] presented a critical review and not a
systematic review or meta-analysis, while Wei’s [20] work was an overview of the current literature, and
Dornhorst et al. [21] presented a reflection undertaken back in 2002.
In contrast, the present study is a systematic review and meta-analysis of RCT that seeks to
determine whether supplementation of vitamin D given alone to women with GDM promotes glycaemic
control during the course of pregnancy.
Our research goal is therefore to determine whether vitamin D supplementation is effective in
improving glycaemia in women with GDM compared to women with GDM who had no vitamin
D supplementation.
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2. Materials and Methods
This systematic review and meta-analysis were conducted in accordance with the preferred
reporting items for systematic reviews and meta-analyses (PRISMA) [24], and followed an a priori, but
unpublished protocol available upon request.
2.1. Data Sources and Search Strategy
Embase (https://www.embase.com/) and PubMed (https://www.ncbi.nlm.nih.gov/pubmed/) were
systematically searched for records from database inception to 20th November 2018 using keywords
(Gestational Diabetes Mellitus; Vitamin D supplementation; Randomised Controlled Trial) and
subject/medical subject heading (MeSH) (Appendix A) based on Participants, Intervention, Comparator,
Outcomes, Study design (PICOS) framework [25]. A hand reference search of the available literature
was also performed. All citations from database searches were exported to Excel and duplicates
were removed.
2.2. Eligibility Criteria
Inclusion criteria were: (1) The use of only vitamin D supplementation; (2) a population of women
with GDM irrespective of age or the number of previous births; (3) studies carried out only during
pre-natal period; (4) an RCT design with an intervention and no-intervention (i.e., control group or
placebo); (5) a definition of GDM where a diagnosis was based on international and local criteria
(6) papers written in English.
Exclusion criteria were: Any study that was not an RCT; studies involving healthy pregnant
women without GDM; studies including women with pre-existing type 1 or type 2 diabetes diagnosed
before pregnancy; studies involving vitamin D and co-supplementation, and studies carried out after
delivery or post-partum.
2.3. Study Selection
One author (E.J.V.) scanned all article titles and abstracts for eligibility, and then performed a
second search of the full text for potentially eligible articles retained from the first search to reach a
final list of included studies. This process was replicated by another author (O.O.). All remaining
authors spot-checked the included and excluded abstracts for consistency with the eligibility criteria.
The search strategy conducted produced 335 records. One additional record was identified
through a hand reference search. 213 records remained once duplicates were removed. After an
inspection of title and abstracts, a further 150 records were excluded. Of the 63 extracted records, five
papers were included in the systematic review and meta-analysis (Figure 1).
2.4. Quality Evaluation
The Critical Appraisal Skills Programme (CASP) checklist for RCTs was used to evaluate the
quality of the studies included in the review [26]. The Cochrane Collaboration tool was used to
assess the risk of bias of each included study. Two authors (S.M.W. and E.J.V.) assessed each study
independently against the seven criteria, including selection bias, performance bias, personal bias,
detection bias, attrition bias and reporting bias [27]. Assessments were made using the information
provided in the published paper only.
2.5. Information Extraction
Information was extracted from the studies into an extraction table (Table 1); that documented
study year, country, type of study, study dates, length of study, sample size, mean age of mother,
intervention, outcome measures of interest, risk of biases, study results and the criteria for defining
GDM. Table 2 provided the estimated average daily intake of Vitamin D and pre-intervention Vitamin
D levels in blood/serum. The data were extracted and crosschecked by three authors.
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Figure 1. Preferr d reporting items for systematic rev ews and meta-analyses (PRISMA) study selection.
For the meta-analysis, the following outcome measures (metabolic parameters) of interests were
extracted (where available) from each study:
• fasting plasma glucose (FPG) (mmol/L)
• glycated haemoglobin (HbA1c) (%)
• serum insulin concentration (µIU/mL)
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Fasting plasma glucose and glycated haemoglobin were selected as outcomes of interest as these
are short- and longer-term measures of glycaemic control respectively. These parameters have also been
linked to neonatal and maternal outcomes, including pre-eclampsia and birthweight [28]. In addition,
the role of serum insulin in glucose homeostasis has been the subject of intense research.
2.6. Data Synthesis and Statistical Analyses
RevMan (Review Manager, 5.3, (Copenhagen, Denmark) [29] was used for meta-analysis
and sensitivity analysis. Since the time, location, population of studies and dosage of vitamin
D supplementation were varied, this is likely to result in heterogeneity in effect size and thus a random
effects models were used to pool the data, rather than a fixed-effect model which assumes a single,
common effect size across studies. Forest plots were depicted to visually assess the effect sizes, the
difference in means and 95% confidence interval (CIs) across the studies.
Heterogeneity across studies was assessed with the Cochrane Q test and a significance level of
p < 0.10 was used to determine statistical significance [27]. In addition, the I2 statistic (from 0 to 100%)
with higher values representing greater inconsistency in effect size across studies was computed [30].
The test for publication bias would have been conducted using a funnel plot and Eggers test if we had
ten or more studies with an outcome of interest.
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Table 1. Data extraction table for all included studies.
Citation Country Type of Study Study Dates Length ofStudy
Sample Size
(Intervention,
Control-Placebo)
Mean Age
of Mother
Time of
Vitamin D
Intervention
Intervention
Outcome
Measures
of Interest
Risk of Biases Study Results
#Asemi et al.
(2013a) [31] Iran
Randomized,
double-blinded,
placebo
controlled
clinical trial
Jan 2013–April
2013 6 weeks 54 (27,27) 31.5± 6.1 years
At 24–28
weeks of
gestation
50,000 IU Vitamin D3
supplements at
baseline and at day
21
FPG, SI
concentration
6/7 low risk
1 high risk for
attrition bias
Change from baseline: Vitamin D group
versus the control
FBG
−17.12 ± 14.84 compared with
−0.96 ± 16.64 mg/dL; p < 0.001-
SI Concentration
−3.08 ± 6.62 compared with
1.34 ± 6.51 µIU/mL; p = 0.01
ANOVA
#Li and Xing,
(2016) [32] China
Randomized
Study Design
Between early
November and
late February
each year from
2010 to 2014
16 weeks 97 (48,49) 24–32 yearsold
At 13
weeks of
gestation
2 servings (200g) of
supplemented
yogurt per day (500
IU vitamin D3 per
serving)
FPG, SI
concentration 7/7 low risk
Change from baseline: Vitamin D group
versus the control
FBG
−9.9 ± 7.2 compared with
2.9 ± 7.6 mg/dL; p = 0.04
SI Concentration
−1.9 ± 4.9 compared with
5.0 ± 5.8 µIU/mL; p = 0.03
t-test
##Zhang et al.
(2016) [33] China
Randomized,
double-blind
placebo-controlled
clinical trial
Sept 2009–Nov
2014 4 weeks 133 (38,20) ** 29.8± 4.7 years
At 24–28
weeks of
gestation
Low dosage: 200 IU
Vitamin D
supplement daily
Medium dosage:
2000 IU daily for 25
days
High dosage: 4000
daily for 12.5 days
FPG, SI
concentration
6/7 low risk
1 unclear risk for
attrition bias
FBG
Low: 96.12; Medium: 88.59; High: 84.73
vitamin D supplementation compared
with control: 92.49 mg/dL; p > 0.05
SI Concentration
Medium: 5.01; High: 4.2 vitamin D
supplementation compared with
control: 9.21 IU/mL; p < 0.01
Non-parametric tests
###Yazdchi et al.,
(2016) [34] Iran
Randomized,
double-blinded,
placebo-controlled
clinical trial
July 2013–Sept
2014 8 weeks 72 (36,36) 31.88± 4.0 years
At 24–28
weeks of
gestation
4 oral treatments of
50,000 IU of Vitamin
D3 (one capsule
every 2 weeks)
FPG, SI
concentration
HbA1c
7/7 low risk
Change from baseline: Vitamin D group
versus the control
FBG
−4.72 ± 13.99 compared with
5.27 ± 9.93 mg/dL; p = 0.01
SI Concentration
1.80 (−1.67–3.77) compared with −0.45
(−1.07–1.35) µIU/mL; p = 0.23
HbA1c
−0.18% ± 0.48% compared with
0.17% ± 0.39%; p = 0.02
ANCOVA
####Hosseinzadeh-
Shamsi-Anar
et al. (2012) [7]
Iran Randomizedclinical trial
Study dates not
provided 12 weeks 45 (24,21) 30.7± 6.2 years
At 24–28
week
gestation
Intramuscular
300,000 IU of vitamin
D
HbA1c
5/7 low risk
1 unclear risk for
selection bias
1 high risk for
performance bias
Vitamin D group versus control
HbA1c
5.58% ± 12 compared with 5.21±0.52%
p = 0.2
t-test
Abbreviations: ANCOVA (analysis of covariance); ANOVA (analysis of variance); FBG (fasting blood glucose); HbA1c (glycated haemoglobin); SI (serum insulin). Criteria for Defining
GDM (# = Criteria set by the American Diabetes Association; ## = Local criteria; ### = International Association of Diabetes and Pregnancy Study groups criteria; #### = Carpenter and
Coustan Criteria for screening tests for gestational diabetes). ** Results for the medium dosage used by the authors (see 3.2 Data inclusion decisions and discrepancies).
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Table 2. Estimated Average Daily Intake of Vitamin D and Pre-Intervention Vitamin D Levels in Blood/Serum.
Citation Interventions
Estimated Average
Intake of Vitamin D Per
Day IU/day
Pre-Intervention Vitamin
D Level in Blood/Serum
Asemi et al. (2013a) [31]
Vitamin D 4762 20.44 ± 14.31 *
Control Placebo 20.41 ± 13.43 *
Li and Xing, (2016) [32]
Vitamin D supplemented
Yoghurt 1000 16.8 ± 4.6 *
Plain Yoghurt Plain Yoghurt 16.2 ± 3.4 *
Zhang et al. (2016) [33]
Vitamin D 2000
Actual values not stated.
Vit. D deficiency (<20
ng/mL)
Control Placebo
Actual values not stated.
Vit. D deficiency (<20
ng/mL)
Yazdchi et al., (2016) [34]
Vitamin D 3333 9.54 (Median) (6.12–15.94)(25th and 75th percentile)
Control Placebo 9.02 (Median) (7.29–14.70)(25th and 75th percentile)
Hosseinzadeh-Shamsi-Anar et al.
(2012) [7]
Vitamin D 3333 24.25 nmol/L (Median)(13.3–202.4) (Min–Max)
Control No Vitamin D 25.30 nmol/L (Median)(12.8–137.2) (Min–Max)
Note: * ng/mL (Mean ± SD).
3. Results
3.1. Study Selection
All studies included were published during 2012–2016. Of the five studies included in the
systematic review, three of the studies were conducted in Iran and two in China. Study length varied
between 4–16 weeks (Table 1). The sample size for the vitamin D supplemented group in the studies
selected ranged from 24–48 while for the control group it ranged from 20–49. The mean age of
the mother taking part in the study was 28 years of age. GDM screening was conducted anytime
between 13 weeks and 28 weeks gestation. Vitamin D supplementation intervention amounts, and
times given varied across all studies (Table 2), however a pattern of 50,000 IU given at least twice
within the study emerged. Administration of vitamin D supplementation was orally (tablets and
vitamin D supplemented yoghurt) and by injection. Outcome measures of interest differed across
studies; however, FPG, glycated haemoglobin and serum insulin concentration were the most regularly
reported. The majority of studies reported a beneficial effect of vitamin D on GDM.
3.2. Data Inclusion Decisions and Discrepancies
Zhang et al. [33] dosed participants according to low, medium and high levels of Vitamin D.
This posed an issue regarding what dosage to use for our meta-analysis. We emailed the authors of the
article, but, received no response. We, therefore, chose the medium dose results to include in this study,
due to it having the closest similarities to the other studies of interest. Another issue in this study
was a discrepancy between the results presented in the text and those presented in the graphs. There
appeared to have been a mix up between the control and low dosage group for fasting plasma glucose,
and the medium and high dosage groups for serum insulin concentrations. The differences were
minimal and we, therefore, decided to use the text results over the graph results. Standard deviations
were not presented in the text and therefore the graphs were converted in Web Plot Digitiser in order
to obtain these.
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3.3. Assessment of The Risk of Bias
Results of the Cochrane risk of bias assessments (Figures 2 and 3) present an overall low risk of
bias, especially in relation to random sequence generation. A slightly higher risk was reported for
performance bias, and attrition bias. Unclear risks were related to selection bias and attrition bias.
Publication bias could not be conducted, due to limited data.
Int. J. Environ. Res. Public Health 2019, 16, x  9 of 17 
 
3. Results 
3.1. Study Selection 
All studies included were published during 2012–2016. Of the five studies included in the 
systematic review, three of the studies were conducted in Iran and two in China. Study length varied 
between 4–16 weeks (Table 1). The sample size for the vitamin D supplemented group in the studies 
selected ranged from 24–48 while for the control group it ranged from 20–49. The mean age of the 
mother taking part in the study was 28 years of age. GDM screening was conducted anytime between 
13 weeks and 28 weeks gestation. Vitamin D supplementation intervention amounts, and times given 
varied across all studies (Table 2), however a pattern of 50,000 IU given at least twice within the study 
emerged. Administration of vitamin D supplementation was orally (tablets and vitamin D 
supplemented yoghurt) and by injection. Outcome measures of interest differed across studies; 
however, FPG, glycated haemoglobin and serum insulin concentration were the most regularly 
reported. The majority of studies reported a beneficial effect of vitamin D on GDM. 
3.2. Data Inclusion Decisions and Discrepancies 
Zhang et al. [33] dosed participants according to low, medium and high levels of Vitamin D. 
This posed an issue regarding what dosage to use for our meta-analysis. We emailed the authors of 
the article, but, received no response. We, therefore, chose the medium dose results to include in this 
study, due to it having the closest similarities to the other studies of interest. Another issue in this 
study was a discrepancy between the results presented in the text and those presented in the graphs. 
There appeared to have been a mix up between the control and low dosage group for fasting plasma 
glucose, and the medium and high dosage groups for serum insulin concentrations. The differences 
were minimal and we, therefore, decided to use the text results over the graph results. Standard 
deviations were not presented in the text and therefore the graphs were converted in Web Plot 
Digitiser in order to obtain these. 
3.3. Assessment of The Risk of Bias 
Results of the Cochrane risk of bias assessments (Figures 2 and 3) present an overall low risk of 
bias, especially in relation to random sequence generation. A slightly higher risk was reported for 
performance bias, and attrition bias. Unclear risks were related to selection bias  and attrition bias. 
Publication bias could not be conducted, due to limited data. 
 
Figure 2. Risk of bias graph per type of bias assessed. Fig re 2. Risk of bias graph per type of bias assessed.Int. J. Environ. Res. Public Health 2019, 16, x  10 of 17 
 
 
Figure 3. Risk of bias summary for the studies assessed. 
3.4. Effect of Vitamin D Supplementation During Pregnancy on Metabolic Parameters 
We performed meta-analysis and sensitivity analysis by removing studies in turn in respect of 
the fasting blood glucose (Figures 4a,b) and serum insulin concentration (Figures 6a,b). Overall the 
mean difference between the intervention and control group was statistically significant in respect of 
fasting blood glucose (p < 0.001) and glycated haemoglobin (p < 0.01) (Figure 5). This result indicates 
that vitamin D supplementation during pregnancy decreases fasting blood glucose by a mean of 0.46 
mmol/L (−0.68, −0.25). The level of heterogeneity analysed across the studies was not significant (p = 
0.16) with a low I2 (41%). The sensitivity analysis also showed a significant improvement (p = 0.007) 
in the group supplemented with vitamin D compared to the control group in relation to fasting blood 
glucose (Figure 4b). A further sensitivity analysis involving the exclusion of the other studies in turn 
demonstrated similar findings to the results of the meta-analysis (p < 0.01) 
For glycated haemoglobin, the two studies included had contrasting findings. However, the 
mean difference between the vitamin D supplementation group and control was also significant (p < 
0.01) with the vitamin D supplementation decreasing glycated haemoglobin by a mean of 0.37% 
(−0.65, −0.08) (Figure 5). 
Regarding the effect of vitamin D supplementation during pregnancy on serum insulin 
concentration, the meta-analysis results of three studies revealed a decline by mean of 4.10 µIU/mL 
(−5.50, −2.71), which is statistically significant at p < 0.001 (Figure 6a). Heterogeneity was insignificant 
(p = 0.46) with an I2 of 0%. The sensitivity test of serum insulin concentration revealed a significant 
decline (p < 0.001) in the group supplemented with vitamin D compared with control group with a 
mean difference of −4.85 µIU/mL (Figure 6b). Similar findings (p < 0.001) were observed by removing 
other studies in turn. 
  
i r . t i .
Int. J. Environ. Res. Public Health 2019, 16, 1716 9 of 15
3.4. Effect of Vitamin D Supplementation During Pregnancy on Metabolic Parameters
We performed meta-analysis and sensitivity analysis by removing studies in turn in respect of
the fasting blood glucose (Figure 4a,b) and serum insulin concentration (Figure 6a,b). Overall the
mean difference between the intervention and control group was statistically significant in respect of
fasting blood glucose (p < 0.001) and glycated haemoglobin (p < 0.01) (Figure 5). This result indicates
that vitamin D supplementation during pregnancy decreases fasting blood glucose by a mean of
0.46 mmol/L (−0.68, −0.25). The level of heterogeneity analysed across the studies was not significant
(p = 0.16) with a low I2 (41%). The sensitivity analysis also showed a significant improvement (p = 0.007)
in the group supplemented with vitamin D compared to the control group in relation to fasting blood
glucose (Figure 4b). A further sensitivity analysis involving the exclusion of the other studies in turn
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For glycated haemoglobin, the two studies included had contrasting findings. However, the mean
difference between the vitamin D supplementation group and control was also significant (p < 0.01)
with the vitamin D supplementation decreasing glycated haemoglobin by a mean of 0.37% (−0.65,
−0.08) (Figure 5).
Regarding the effect of vitamin D supplementation during pregnancy on serum insulin
concentration, the meta-analysis results of three studies revealed a decline by mean of 4.10 µIU/mL
(−5.50, −2.71), which is statistically significant at p < 0.001 (Figure 6a). Heterogeneity was insignificant
(p = 0.46) with an I2 of 0%. The sensitivity test of serum insulin concentration revealed a significant
decline (p < 0.001) in the group supplemented with vitamin D compared with control group with a
mean difference of −4.85 µIU/mL (Figure 6b). Similar findings (p < 0.001) were observed by removing
other studies in turn.
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4. Discussion
The results of the systematic review and meta-analysis show that vitamin D supplementation
has a significant effect on serum insulin and blood glucose parameters. These results were confirmed
by the sensitivity analyses. In particular, there were significant decreases in fasting blood glucose,
glycated haemoglobin and serum insulin concentrations in women with GDM compared with the
control groups. These findings provide more robust evidence compared with the results of previous
systematic reviews and meta-analysis of observational studies involving vitamin D and GDM [6,14,16].
These earlier studies indicated a consistent association between vitamin D deficiency and increased
risk of GDM and that supplementation of vitamin D could ameliorate the condition, but, it remains
unclear whether this association is actually caused by vitamin D. The present review addresses the
limitations of previous observational studies by including only RCTs which were needed to fully elicit
the impact of vitamin D supplementation on women with GDM. Treatments in observational studies
are not allocated by chance and thus are likely to give rise to the imbalance between the groups being
compared [35].
The present review is also different from previous reviews which were based on RCTs. Roth et al.’s [23]
review included vitamin D supplementation given in combination with a co-intervention, while
Akbari et al. [22] in their review selected studies that combined vitamin D with calcium (Asemi et al. [36]) and
studies (Mozffari-Khosravi et al. [37]; Valizadeh et al. [38]) that involved post-partum women. In contrast,
the present review is unique and the first that is based on RCTs of vitamin D supplementation given
alone and focuses on women with gestational diabetes and their glycaemic outcomes before parturition.
Therefore, while Akbari et al. [22] found no significant differences between the groups supplemented
with vitamin D and control in terms of fasting blood glucose, glycated haemoglobin and insulin levels,
the current review found significant (p < 0.05) improvement in the vitamin D supplemented group
compared with control in relation to these parameters. According to Hodson et al. [2], the sensitivity to
insulin decreases progressively during pregnancy and returns swiftly to normal following delivery.
Thus, the inclusion of studies involving participants who had delivered may have influenced the
results of the Akbari et al. [22] study when compared to our review which included only pre-natal
women with GDM.
While previous studies have tended to focus primarily on the broader association between vitamin
D and gestational diabetes, maternal and/or neonatal endpoints and less on metabolic parameters, the
present review sees these outcomes as interrelated. For example, the metabolic parameters, including
fasting blood glucose and glycated haemoglobin have been reported in some studies as the major
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factors in GDM that influence clinical outcomes, such as birthweight. Therefore, their evaluation
is critical in understanding the pathways of the clinical manifestations of maternal and neonatal
outcomes. There is evidence that glycated haemoglobin can be used to estimate the risk of pregnancy
complications [39]. Furthermore, the Hyperglycaemia and Adverse Pregnancy Outcome (HAPO)
study involving 25,505 pregnant women has demonstrated strong associations of maternal glucose
levels below the diagnosis level for diabetes with increased birthweight [28].
Rudnicki and Molsted–Perdersen [40] evaluated the effect of 1,25-dihydrovitamin D supplement
on glucose metabolism in 12 women with gestational diabetes. The results showed that intravenous
1,25 dihydroxyvitamin D3 significantly decreased fasting blood glucose levels in GDM although the
differences were not significant following 14 days of oral vitamin D supplementation. The authors
concluded that the administration of vitamin D3 tends to decrease fasting blood glucose. Similarly,
Asemi et al. [41] found that vitamin D supplementation over nine weeks significantly decreased fasting
plasma glucose, insulin concentrations and significantly increased insulin sensitivity. The findings of
the current systematic review and meta-analysis support these earlier results.
Rudnicki and Molsted – Perdersen [40] noted that the level of insulin decreased after intravenous
and oral treatment with vitamin D. Therefore, the decrease in the levels of fasting blood glucose and
glycated haemoglobin observed in the current review may be due to the action of vitamin D through
the increased cellular absorption of glucose either directly or by enhancing the action of insulin [40].
In other words, the lower insulin levels detected in the current review in the vitamin D group compared
with the control group would suggest that the mechanism of improved glucose tolerance was not due to
increased production of insulin, but potentially from an increased sensitivity to the action of insulin [9].
Vitamin D has been shown to improve insulin sensitivity in target cells (liver, skeletal muscle and
adipose tissue) and protect them from the detrimental effects of immune attack [42]. The mechanism
of vitamin D action in glucose homeostasis in GDM may involve stimulating the expression of insulin
receptors in peripheral tissues, thus, regulating the uptake of glucose [43,44]. Insulin mediated glucose
uptake is dependent on calcium; therefore, the vitamin D status may indirectly influence glucose
transport in target tissues through the regulation of intracellular calcium [14,44]. The different actions of
vitamin D may explain why previous studies have suggested that the effect of vitamin D on glucose may
be through its influence on insulin secretion in the pancreatic beta cells [40,45]. Based on the different
views on the role of vitamin D in glucose homeostasis, it is safe to suggest that further studies are
needed to fully understand the exact mechanism by which vitamin D influences glucose metabolism.
Drawing from the results of this review and meta-analysis, it could be argued that vitamin D has
a role in maintaining glucose homeostasis and thus has clinical and public health implications. In this
regard, the National Institute for Health and Care Excellence (NICE) [46] has recommended increased
access to vitamin D supplements for pregnant women to ensure that they meet the Reference Nutrient
Intake. NICE [46] recommended that the Department of Health should work with manufacturers to
ensure that vitamin D supplements providing the Reference Nutrient Intake of 10 micrograms per day
of vitamin D for pregnant women are available. Boucher et al. [47] also recommended that women
should be provided with vitamin D supplements as currently recommended nationally for pregnancy.
In addition, the Royal College of Obstetricians and Gynaecologists (RCOG) [48], noted that, daily
vitamin D supplementation with oral cholecalciferol or ergocalciferol is safe in pregnancy and that
vitamin D 10 microgram (400 units) a day should be provided for all pregnant women in line with
national guidelines. Pregnant women should also be encouraged to receive adequate nutrition which
is best accomplished through the consumption of a healthy balanced diet [49,50].
Limitations
A strength of this review is its focus on RCTs. Although most of the studies were graded as
having either low risk or moderate risk of bias while two studies had a high risk of bias in the areas
of blinding of participants and personnel, and incomplete outcome data, within each RCT included
there was variation in the amount, route and timings of vitamin D dosages given. Outcomes were
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based on studies conducted in only two countries, and RCT studies available for meta-analysis were
very few and the sample sizes were small. In addition, the exclusion of studies not written in English
may have limited the number of studies included in this review. Some discrepancies were found in
Zhang et al. [33] study. These would affect the validity of the results of this review, thus more studies
are needed to build on the evidence base.
5. Conclusions
This review has demonstrated that vitamin D supplementation has the potential to promote
glycaemic control in women with GDM. However, due to the limited number of studies in the
meta-analysis, the conclusion should be interpreted with caution. Further studies are needed to fully
understand the exact mechanism by which vitamin D influences glucose metabolism.
Author Contributions: The protocol for this review was written by O.O., S.M.W. and T.T., E.J.V., T.T. and S.M.W.
participated in the searches and in extracting data from the articles reviewed. O.O. carried out the data analysis.
S.M.W. and O.O. wrote the initial draft, which was reviewed and revised by O.O., S.M.W. and T.T.
Funding: This research was funded by the University of Greenwich as part of their QR competitive funding grants.
Acknowledgments: We would like to thank Jude Ibe for his contribution in meetings during the initial stages.
Conflicts of Interest: The authors declare no conflict of interest.
Appendix A Search Terms
Embase
Search date: up to 20 November 2018
Database: Embase <1974 to current >
1. exp pregnancy diabetes mellitus/or Gestational diabetes.mp. or GDM.mp. or gestational diabetes
mellitus.mp. or diabetes mellitus, gestational.mp. or diabetes in pregnancy.mp (33032).
2. exp vitamin D/or Vitamin D.mp. or 25- hydroxyvitamin D.mp. or 25OHD.mp. or calciferol.mp.
or ergocalciferol.mp. or cholecalciferol.mp (144930).
3. exp randomized controlled trial/or Randomised controlled trial.mp. or Controlled clinical trial.mp.
or Randomized.mp. or Placebo.mp (1357496).
4. 1 and 2 and 3 (138).
5. limit 4 to human (134).
Pubmed
Search: up to 20 November 2018
#1 Gestational diabetes OR GDM OR gestational diabetes mellitus OR diabetes mellitus, gestational OR
diabetes in pregnancy OR Diabetes, gestational [MeSH] OR pregnancy in diabetics [MeSH] (37699).
#2 Vitamin D OR 25-hydroxyvitamin D OR 25OHD OR calciferol OR ergocalciferol OR cholecalciferol
OR Vitamin D [MeSH] (79485).
#3 Randomised controlled trial OR Controlled clinical trial OR Randomized OR Placebo OR
Drug therapy OR randomly OR trial OR groups OR “Randomized Controlled Trials as Topic”
[MeSH] (5428822).
#4 Animals [MeSH] NOT Humans [MeSH] (4517123).
#5 #1 AND #2 AND #3 (208).
#6 #5 NOT #4 (201).
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